Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy von Neubauer, Horst, Kaiser, Andreas F C, Endres, Heinz G, Krüger, Jan C, Engelhardt, Andreas, Lask, Sebastian, Pepinghege, Fenena, Kusber, Andreas, Mügge, Andreas

Volltext

Cytochrome P450 2B6 and 2C9 genotype polymorphism – a possible cause of prasugrel low responsiveness von Franken, Cora C., Kaiser, Andreas F. C., Krüger, Jan C., Overbeck, Kristina, Mügge, Andreas, Neubauer, Horst

Volltext

Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD von Meves, Saskia H., Hummel, Thomas, Endres, Heinz G., Mayböck, Nora, Kaiser, Andreas F. C., Schröder, Kay D., Rüdiger, Katja, Overbeck, Ursula, Mumme, Achim, Mügge, Andreas, Neubauer, Horst

Volltext

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan von Lask, Sebastian, Kusber, Andreas, Endres, Heinz G, Engelhardt, Andreas, Neubauer, Horst, Krüger, Jan C, Mügge, Andreas, Kaiser, Andreas F.C, Pepinghege, Fenena

Volltext